According to reports from The Financial Express, two Indian pharmaceutical companies have emerged as standout performers with return on capital employed above 20% and negligible debt. Amrutanjan Health Care achieved a 25% ROCE in FY26, roughly double the industry median, while Jagsonpal Pharmaceuticals recorded 23% ROCE, also close to double the sector average. Both companies maintain minimal debt levels with Amrutanjan holding ₹2 crore in borrowings against reserves of ₹367 crore, and Jagsonpal showing ₹8 crore in borrowings with ₹191 crore in free cash as of March 2026.
As reported by The Financial Express, Amrutanjan Health Care commissioned a ₹150 crore greenfield sanitary napkin plant in Telangana's Rangareddy district in August 2026, featuring two high-speed Japanese lines capable of producing 700 million napkins annually. The company's women's hygiene and personal care segment showed strong growth with 27% increase to ₹36.36 crore in the June 2026 quarter, while the traditional balm franchise remained stagnant at ₹57.26 crore, up only 0.5%. However, the expansion has created immediate financial pressure with capital work in progress jumping from ₹16 crore to ₹106 crore and free cash flow turning negative by ₹19 crore in FY26.
According to The Financial Express, Jagsonpal Pharmaceuticals demonstrated impressive margin expansion with operating margin improving from 10% in FY21 to 20% in FY26. The company completed the acquisition of 85% stake in Aequitas Healthcare for ₹20.8 crore in July 2026, targeting ₹10 crore EBITDA by year two and ₹100 crore revenue within two and a half years. The company's top five brands contribute 47% of revenue with 17 brands ranking in top five of their respective molecule categories, supported by a field force of more than 900 people.
As reported by The Financial Express, Amrutanjan Health Care shares closed at ₹491 on September 11, 2026, down approximately 35% over a year and trading at a PE of 23x compared to the industry median of 35x. Jagsonpal Pharmaceuticals closed at ₹233 on September 11, 2026, showing a 5-year price CAGR of 29% and 10-year CAGR of 32%, though down 3% over the past year. Both companies offer attractive dividend yields with Amrutanjan providing 1% yield and Jagsonpal offering 1.7% yield, including special components that may not represent sustainable payout rates.
According to The Financial Express, both companies face distinct challenges despite strong fundamentals. Amrutanjan requires pain management volumes to recover after a 3.4% decline in the June quarter, while the new manufacturing plant must achieve full capacity utilization. Jagsonpal depends on the Aequitas acquisition to generate meaningful returns, with the hospital distribution channel currently generating minimal profitability. The analysis suggests both companies warrant close monitoring rather than immediate investment, as their future performance will largely depend on execution of expansion plans and market recovery in their respective segments.
